Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

Blauvelt A.; Lacour J. -P.; Fowler J. F.; Weinberg J. M.; Gospodinov D.; Schuck E.; Jauch-Lembach J.; Balfour A.; Leonardi C. L.

首页> 外文期刊>British Journal of Dermatology >Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

【24h】

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

机译：III期随机研究提出的牛皮癣拟议的Adalimalab生物仿制GP2017：多个开关的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundAdalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar.

机译：BackgroundAdalimumab用于治疗几种炎症性疾病，包括斑块性牛皮癣。 GP2017是一个提出的Adalimalab BioSimilar。

著录项

来源
《British Journal of Dermatology》 |2018年第3期|共9页
作者
Blauvelt A.; Lacour J. -P.; Fowler J. F.; Weinberg J. M.; Gospodinov D.; Schuck E.; Jauch-Lembach J.; Balfour A.; Leonardi C. L.;
展开▼
作者单位

Oregon Med Res Ctr Portland OR USA;

Univ Nice Sophia Antipolis Nice France;

Dermatol Specialists Louisville KY USA;

Mt Sinai Sch Med New York NY USA;

Med Univ Pleven Bulgaria;

Hexal AG Holzkirchen Germany;

Hexal AG Holzkirchen Germany;

Hexal AG Holzkirchen Germany;

Cent Dermatol St Louis MO 63117 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches [J] . Blauvelt A., Lacour J. -P., Fowler J. F., British Journal of Dermatology . 2018,第3期

机译：III期随机研究提出的牛皮癣拟议的Adalimalab生物仿制GP2017：多个开关的影响
2. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study [J] . Papp Kim, Bachelez Herve, Costanzo Antonio, Journal of the American Academy of Dermatology . 2017,第6期

机译：BioSimilar ABP 501对Adalimalab治疗中度至重度斑块牛皮癣患者的临床相似性：随机，双盲，多中心，第三阶段研究
3. Phase III III Randomized Study of SB SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis [J] . Weinblatt Michael E., Baranauskaite Asta, Niebrzydowski Jaroslaw, Arthritis & rheumatology. . 2018,第1期

机译：III期III III，SB SB 5的随机研究，一种Adalimalab BioSimilar，与中生至重度类风湿性关节炎患者的参考剂Adalimalab
4. iClassMFT: Proposed Multiple Flow Tables Classes to Integrate Security and Flexibility into SDN Switches [C] . Edwardes Amaro Galhardo, Antonio Carlos Oliveira Junior International Conference on Computational Science and Computational Intelligence . 2019

机译：iClassMFT：建议的多个流表类，以将安全性和灵活性集成到SDN交换机中
5. Bayesian Sequential Randomization Designs for Phase III Clinical Trials. [D] . Zhu, Han. 2016

机译：III期临床试验的贝叶斯顺序随机设计。
6. Multiple switches between GP2015 an etanercept biosimilar with originator product do not impact efficacy safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3 confirmatory EGALITY study [O] . S. Gerdes, D. Thaçi, C.E.M. Griffiths, -1

机译：依那西普生物仿制药与原始产品GP2015之间的多次切换不会影响慢性斑块状牛皮癣患者的功效安全性和免疫原性：3期临床试验30周证实性EGALITY研究
7. AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis [O] . J. Hercogová, K.A. Papp, V. Chyrok, 2019

机译：AURIEL -PSO：随机的双盲期III等效试验，以证明所提出的生物拖尾MSB 11022在中度至严重的慢性噬斑型牛皮癣患者中参考患者的临床相似性

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

摘要

著录项

相似文献

相关主题

期刊订阅